drugset / Trial / NCT04296786
Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study
Phase 2
Unknown
52 enrolled
Peking Union Medical College Hospital
Beijing Longfu Hospital · collabDongzhimen Hospital, Beijing · collabPeking University Third Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of Sintilimab combined with Chidamide in the treatment of relapsed/refractory cutaneous T-cell lymphoma.
Timeline
- Start
- 2019-11-01
- Primary completion
- 2022-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |